Neuropsychology and neuroimaging profiles of amyloid‐positive versus amyloid‐negative amnestic mild cognitive impairment patients

Tomadesso, Clémence; Sayette, Vincent de La; Flores, Robin de; Bourgeat, Pierrick; Villemagne, Victor L.; Egret, Stéphanie; Eustache, Francis; Chételat, Gaël

doi:10.1016/j.dadm.2018.02.008

Cited by 18 publications

(20 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our 144 MCI patients, only 9.7% showed amyloid positivity. The rate of amyloid positivity waslower than previous studies, which have reported that 41-75% of MCI patients show beta amyloid retention on amyloid PET imaging (33)(34)(35). The criteria provided for MCI by Winblad et al used in our study are relatively general, which may explain the low rate of amyloid positivity found in MCI patients in the present study.…”

Section: Discussioncontrasting

confidence: 80%

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

Shi

Zhang

et al. 2020

J Nucl Med

View full text Add to dashboard Cite

Cerebral β-amyloid deposits and regional glucose metabolism assessed by positron emission tomography (PET) are used to distinguish between Alzheimer's disease (AD) and other dementia syndromes. In the present multicenter study, we estimated the prevalence of β-amyloid deposits on PET imaging in a wide variety of dementia syndromes and mild cognitive impairment (MCI) within a memory clinic population. Methods: Of the 1193 consecutive patients with cognitive impairment (CI) who received combined 18 F-AV45 and/or 11 C-PIB PET, 960 were diagnosed with AD, 36 with frontotemporal dementia (FTD), 5 with dementia with Lewy bodies (DLB), 144 with MCI, 29with vascular dementia (VaD), 4 with corticobasal syndrome (CBS) and 15 with unclassifiable dementia. Baseline clinical diagnoses were independently established without access to PET imaging results. ApoE genotype analysis was performed in CI patients and 231 gender-and age-matched controls. Results: Of the 1193 CI patients, 860 (72.1%) were amyloid-positive. The prevalence of amyloid positivity in AD and MCI patients was 86.8% (833/960) and 9.7% (14/144), respectively. In FTD patients, the prevalence of β-amyloid deposits was 5.6% (2/36). In the 4 CBS patients, two were amyloid-positive. Three of the 5 DLB patients showed amyloid positivity, as did 6 of the 29 VaD (20.7%) patients. The ApoEε4 allele frequency was significantly increased in amyloid-positive CI patients (30.5%) as compared with other amyloid-negative CI patients (14%) or controls (7.3%). Conclusions: Amyloid imaging may potentially be the most helpful parameter for differential diagnosis in dementia, particularly to distinguish between AD and FTD. Amyloid PET can be used in conjunction with the ApoEε4 allele genetic risk test for amyloid deposits.

show abstract

Section: Discussioncontrasting

confidence: 80%

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

Shi

Zhang

et al. 2020

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…All examinations were performed at the Cyceron Center (Caen, France). Details on MRI and PET images acquisition and preprocessing are available in previous publications [28,29] and are fully described in the Supplementary Material. Briefly, T1‐weighted images were preprocessed in SPM12.…”

Section: Methodsmentioning

confidence: 99%

Brain and cognitive correlates of sleep fragmentation in elderly subjects with and without cognitive deficits

André

Tomadesso

Flores

et al. 2019

Alz & Dem Diag Ass & Dis Mo

Self Cite

View full text Add to dashboard Cite

Introduction Sleep disturbances are increasingly recognized as a risk factor for Alzheimer's disease. However, no study has assessed the relationships between objective sleep fragmentation (SF) and brain and cognitive integrity across different cognitive stages, from cognitively unimpaired elderly subjects to patients with subjective cognitive decline and/or mild cognitive impairment. Methods 30 cognitively unimpaired elderly participants and 36 patients with subjective cognitive decline and/or mild cognitive impairment underwent a neuropsychological evaluation, structural MRI, 18 F-fluorodeoxyglucose, and 18 F-florbetapir-PET scans, and an actigraphy recording over a minimum of six consecutive nights. Multiple regression and mediation analyses were performed between SF parameters, neuroimaging data, and cognitive scores. Results In cognitively unimpaired elderly participants, SF intensity mediated the association between frontohippocampal hypometabolism and lower executive functioning. Moreover, to a lower extent, increased SF variability was related to thalamic atrophy and ventromedial prefrontal amyloid burden. However, in patients with subjective cognitive decline and/or mild cognitive impairment, SF no longer contributed to the expression of cognitive deficits. Discussion These findings suggest that SF may directly contribute to lower cognitive performance in cognitively unimpaired elderly subjects. Therefore, treating sleep disturbances before the onset of cognitive deficits may help to cope with brain alterations and maintain cognitive functioning.

show abstract

“…Since patients with AD typically have deficits in episodic memory as a consequence of early and marked hippocampal neurodegeneration, it is not surprising that Aβ+ aMCI patients consistently presented more prominent episodic memory deficits than Aβ− aMCI patients in several different studies (Bahar‐Fuchs et al ., 2013; Huijbers et al ., 2015; Kandel, Avants, Gee, Arnold, & Wolk, 2015; Kim et al ., 2018; Reijs et al ., 2017; Tomadesso et al ., 2018, 2019; Wolk et al ., 2009). However, regarding attention and executive functions, different studies produced less consistent results, possibly depending on the kind of test used to measure these abilities as well as the number of patients recruited.…”

Section: Introductionmentioning

confidence: 99%

Neuropsychological profile of amyloid‐positive versus amyloid‐negative amnestic Mild Cognitive Impairment

Alves

Cardoso

Silva

et al. 2020

Journal of Neuropsychology

View full text Add to dashboard Cite

Introduction. Patients diagnosed with amnestic mild cognitive impairment (aMCI) are at high risk of progressing to dementia. It became possible, through the use of biomarkers, to diagnose those patients with aMCI who have Alzheimer's disease. However, it is presently unfeasible that all patients undergo biomarker testing. Since neuropsychological testing is required to make a formal diagnosis of aMCI, it would be interesting if it could be used to predict the amyloid status of patients with aMCI. Methods. Participants with aMCI, known amyloid status (Ab+ or AbÀ) and a comprehensive neuropsychological evaluation, were selected from the Cognitive Complaints Cohort database for this study. Neuropsychological tests were compared in Ab+ and AbÀ aMCI patients. A binary logistic regression analysis was conducted to model the probability of being amyloid positive. Results. Of the 216 aMCI patients studied, 117 were Ab+ and 99 were AbÀ. Ab+ aMCI patients performed worse on several memory tests, namely Word Total Recall, Logical Memory Immediate and Delayed Free Recall, and Verbal Paired Associate Learning, as well as on Trail Making Test B, an executive function test. In a binary logistic regression model, only Logical Memory Delayed Free Recall retained significance, so that for each additional score point in this test, the probability of being amyloid positive decreased by 30.6%. The resulting model correctly classified 64.6% of the aMCI cases regarding their amyloid status.

show abstract

Neuropsychology and neuroimaging profiles of amyloid‐positive versus amyloid‐negative amnestic mild cognitive impairment patients

Cited by 18 publications

References 55 publications

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

Brain and cognitive correlates of sleep fragmentation in elderly subjects with and without cognitive deficits

Neuropsychological profile of amyloid‐positive versus amyloid‐negative amnestic Mild Cognitive Impairment

Contact Info

Product

Resources

About